Cartesian Therapeutics Inc. (RNAC) — Cash Flow Quality Index
Cartesian Therapeutics Inc. (RNAC) has a Cash Flow Quality Index of -1.10x as of June 2025. Operating cash flow of $-17.52 Million is below net income of $15.89 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore RNAC cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cartesian Therapeutics Inc. Cash Flow Quality Index (2022–2022)
Historical Cash Flow Quality Index for Cartesian Therapeutics Inc. across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash efficiency ratio of Cartesian Therapeutics Inc..
Annual Cash Flow Quality Index for Cartesian Therapeutics Inc. (2022–2022)
Year-by-year earnings quality comparison for Cartesian Therapeutics Inc..
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | -0.89x | $-31.63 Million | $35.38 Million | — |